* Resmed Inc RMD.N RMD is expected to show a rise in
quarterly
revenue when it reports results on October 24 for the period
ending September 30 2024
* The San Diego California-based company is expected to
report a
7.1% increase in revenue to $1.18 billion from $1.1 billion a
year ago, according to the mean estimate from 12 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Resmed Inc is for
earnings of
$2.07 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.
* Wall Street's median 12-month price target for Resmed Inc
is
236.33, below its last closing price of $239.98.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 2.05 2.07 2.08 Beat 0.6
Jan. 1 2024 1.92 1.91 2.13 Beat 11.3
Dec. 31 2023 1.80 1.80 1.88 Beat 4.7
Sep. 30 2023 1.61 1.62 1.64 Beat 1.4
Jun. 1.69 1.69 1.60 Missed -5.4
30 2023
Mar. 31 2023 1.59 1.59 1.68 Beat 5.9
Dec. 31 2022 1.63 1.62 1.66 Beat 2.6
Jan. 1 0001 1.52 1.52 1.51 Missed -0.4
This summary was machine generated October 23 at 03:49 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)